[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.52.237. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
The Pediatric Forum
October 2001

Piracetam Study: Poorly Designed and Misinterpreted

Author Affiliations

Not Available

Arch Pediatr Adolesc Med. 2001;155(10):1175-1176. doi:10.1001/archpedi.155.10.1175

I read with great interest the article by Lobaugh et al1 in the April 2001 issue of the ARCHIVES. I recently published 2 original articles on aberrations in intermediary metabolism and the effects of a peptide therapy on partially trisomic Ts65Dn mice, an animal model for Down syndrome. I am familiar with the claims of various Down syndrome advocacy groups on the use of the drug piracetam and with various nutritional intervention strategies to address health issues associated with this genetic disorder. Finally, I was also interviewed and quoted in 2 of the 3 American Broadcasting Corporation programs in which piracetam was discussed.

First Page Preview View Large
First page PDF preview
First page PDF preview
×